Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer.
CONCLUSION: Exemestane given for prevention has limited negative impact on menopause-specific and health-related QOL in healthy postmenopausal women at risk for breast cancer. PMID: 24711552 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 7, 2014 Category: Cancer & Oncology Authors: Maunsell E, Goss PE, Chlebowski RT, Ingle JN, Alés-Martínez JE, Sarto GE, Fabian CJ, Pujol P, Ruiz A, Cooke AL, Hendrix S, Thayer DW, Rowland KM, Dubé P, Spadafora S, Pruthi S, Lickley L, Ellard SL, Cheung AM, Wactawski-Wende J, Gelmon KA, Johnston D, Tags: J Clin Oncol Source Type: research

Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline.
CONCLUSION: The ASCO review panel endorses the SSO/ASTRO recommendations with qualifications, as follows. The panel reinforces and amplifies the guideline authors' call for the monitoring of outcomes of the guideline at the institutional level, as institutions transition to adopting the SSO/ASTRO recommendations; would place greater emphasis on the importance of postlumpectomy mammography for cases involving microcalcifications; and calls for flexibility in the application of the guideline in light of the generally weak evidence supporting the recommendations. PMID: 24711553 [PubMed - as supplied by publisher] (Source...
Source: Clinical Breast Cancer - April 7, 2014 Category: Cancer & Oncology Authors: Buchholz TA, Somerfield MR, Griggs JJ, El-Eid S, Hammond ME, Lyman GH, Mason G, Newman LA Tags: J Clin Oncol Source Type: research

Psychometric Properties of the Japanese Version of the Concerns About Recurrence Scale (CARS-J).
CONCLUSIONS: The results suggest that Japanese version of the concerns about recurrence scale is a reliable and valid clinical research tool to evaluate the fear of recurrence among patients with breast cancer in Japan, although there may be cross-cultural differences regarding factor structures between Western and Japanese breast cancer patients. PMID: 24711631 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 7, 2014 Category: Cancer & Oncology Authors: Momino K, Akechi T, Yamashita T, Fujita T, Hayahi H, Tsunoda N, Miyashita M, Iwata H Tags: Jpn J Clin Oncol Source Type: research

Association of BRCA1 K1183R polymorphism with survival in BRCA1/2-negative chinese familial breast cancer.
CONCLUSIONS: The present study suggests that the AA genotype of BRCA1 K1183R polymorphism is associated with a favorable survival in HER2 positive familial breast cancer patients. PMID: 24600974 [PubMed - indexed for MEDLINE] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2014 Category: Cancer & Oncology Authors: Pei R, Wang P, Zhou Y, Zhang J, Ouyang T, Li B, Xie Y Tags: Clin Lab Source Type: research

p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry.
In this study, we examine the expression profiles of p63 protein in benign proliferative diseases and malignant tumors of the breast using pan-p63 and p40 antibodies, and analyze their diagnostic utility and clinical implications. We selected 32 adenoses, 34 intraductal papillomas, 31 ductal carcinoma in situ (DCIS), 257 invasive ductal carcinoma (IDC), and 36 metaplastic carcinomas, and created tissue microarray blocks from them. Immunohistochemical assays for p63 protein were performed on these samples. We investigated the expression patterns of the pan-p63 (TP63, 4A4, Dako, 1:700), p40 antibody [5-17, CalBiochem/EMD Bio...
Source: Clinical Breast Cancer - April 5, 2014 Category: Cancer & Oncology Authors: Kim SK, Jung WH, Koo JS Tags: Int J Clin Exp Pathol Source Type: research

Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
CONCLUSIONS: Overall, our results support the clinical utility of measuring serum HER2 ECD levels in patients with advanced breast cancer. Baseline and serial measurements of serum ECD levels are reliably predictive of clinical outcome of breast cancer patients. PMID: 24696727 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2014 Category: Cancer & Oncology Authors: Shao X, Wang X, Xu X, Feng J, Han M, Zhang H, Chen ZH, Wang S, Zang YM, Huang P, Jin H, Wang X Tags: Int J Clin Exp Pathol Source Type: research

Over-expression of miR-98 in FFPE tissues might serve as a valuable source for biomarker discovery in breast cancer patients.
This study was to evaluate the potential predictive value of miR-98 expression in formalin-fixed paraffin-embedded tissue of breast cancer patients. The expression levels of miR-98 were examined in 98 breast cancer patients and 40 cancer-free controls using real-time quantitative PCR. The comparison of miR-98 expression levels between patient and control was performed using the Mann-Whitney test. The miR-98 showed higher expression levels in breast cancer patients compared with cancer free controls (p
Source: Clinical Breast Cancer - April 5, 2014 Category: Cancer & Oncology Authors: Deng ZQ, Yin JY, Tang Q, Liu FQ, Qian J, Lin J, Shao R, Zhang M, He L Tags: Int J Clin Exp Pathol Source Type: research

TnI-Ultra assay measurements in cancer patients: Comparison with the conventional assay and clinical implication.
Abstract The serial monitoring of cardiac troponin represents an effective approach for the early identification, assessment, and monitoring of chemotherapy-induced cardiac injury. Over the last few years new generations of troponin assays, referred to as sensitive and high sensitivity assays, able to detect very low concentrations of troponin, have been progressively released on different platforms. Some studies have assessed the comparability of the cTnI measurements with the new assays versus the conventional ones, but none of these in the oncological population. We compared the cTnI results determined on Strat...
Source: Clinical Breast Cancer - April 3, 2014 Category: Cancer & Oncology Authors: Salvatici M, Cardinale D, Botteri E, Bagnardi V, Mauro C, Cassatella MC, Lentati P, Bottari F, Zorzino L, Passerini R, Cipolla CM, Sandri MT Tags: Scand J Clin Lab Invest Source Type: research

Pressure pain sensitivity as a marker for stress and pressure pain sensitivity-guided stress management in women with primary breast cancer.
Abstract Objectives. To validate (1) Pressure Pain Sensitivity (PPS) as a marker for stress and (2) a PPS-guided intervention in women with primary Breast Cancer (BC). Methods. (1) A total of 58 women with BC were examined before and after 6 months of intervention. A control group of 165 women office employees was divided in a High Stress Group (HSG, n = 37) and a Low Stress Group (LSG, n = 128) to evaluate the association between PPS, questionnaire-related Quality of Life (QOL) and self-evaluated stress. (2) A PPS-guided stress management program (n = 40) was compared to a Psychosocial Group Intervention (PGI, n ...
Source: Clinical Breast Cancer - April 3, 2014 Category: Cancer & Oncology Authors: Axelsson CK, Ballegaard S, Karpatschof B, Schousen P Tags: Scand J Clin Lab Invest Source Type: research

Population pharmacokinetic modeling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
Abstract AIMS: Tamoxifen is considered a pro-drug of its active metabolite endoxifen. The major metabolic enzymes involved in endoxifen formation are CYP2D6 and CYP3A. There is considerable evidence that variability in activity of these enzymes influences endoxifen exposure and thereby may influence clinical outcome of tamoxifen treatment. We aimed to quantify the impact of metabolic phenotype on the pharmacokinetics of tamoxifen and endoxifen. METHODS: We assessed the CYP2D6 and CYP3A metabolic phenotypes in 40 breast cancer patients on tamoxifen treatment with a single dose of dextromethorphan as a dual phe...
Source: Clinical Breast Cancer - April 2, 2014 Category: Cancer & Oncology Authors: Ter Heine R, Binkhorst L, de Graan AJ, de Bruijn P, Beijnen JH, Mathijssen RH, Huitema AD Tags: Br J Clin Pharmacol Source Type: research

Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma.
Abstract Similarities between the pathologic progression of cancer and the physiologic process of placentation (eg, proliferation, invasion, and local/systemic tolerance) have been recognized for many years. Sex hormones such as human chorionic gonadotropin, estrogens, progesterone, and others contribute to induction of immunologic tolerance at the beginning of gestation. Sex hormones have been shown to play contributory roles in the growth of cancers such as breast cancer, prostrate cancer, endometrial cancer, and ovarian cancer, but their involvement as putative mediators of the immunologic escape of cancer is s...
Source: Clinical Breast Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, Markovic SN Tags: Mayo Clin Proc Source Type: research

Diagnosis and Management of Benign, Atypical, and Indeterminate Breast Lesions Detected on Core Needle Biopsy.
Abstract Imaging abnormalities detected by mammographic screening often lead to diagnostic evaluations, with suspicious abnormalities subjected to image-guided core needle biopsy (CNB) to exclude malignancy. Most CNBs reveal benign pathological alterations, termed benign breast disease (BBD). Adoption of CNB presents challenges with pathologic classification of breast abnormalities and management of patients with benign or atypical histological findings. Patient management and counseling after CNB diagnosis of BBD depends on postbiopsy determination of radiologic-pathologic concordancy. Communication between radio...
Source: Clinical Breast Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Neal L, Sandhu NP, Hieken TJ, Glazebrook KN, Mac Bride MB, Dilaveri CA, Wahner-Roedler DL, Ghosh K, Visscher DW Tags: Mayo Clin Proc Source Type: research

Breast Density and Breast Cancer Risk: A Practical Review.
Abstract New legislation in several states requiring breast density notification in all mammogram reports has increased awareness of breast density. Estimates indicate that up to 50% of women undergoing mammography will have high breast density; thus, with increased attention and high prevalence of increased breast density, it is crucial that primary care clinicians understand the implications of dense breasts and are able to provide appropriate counseling. This review provides an overview of breast density, specifically by defining breast density, exploring the association between breast density and breast cancer...
Source: Clinical Breast Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Wang AT, Vachon CM, Brandt KR, Ghosh K Tags: Mayo Clin Proc Source Type: research

Increasing certification through unit-based education.
Abstract Certification has been identified by multiple organizations as an important component and means of elevating the level of nursing care provided to patients and demonstrating to the public that the nursing staff has subspecialty knowledge. Certification may lead to improved patient satisfaction and outcomes as well as increased nurse satisfaction and retention. Despite the known potential benefits associated with certification, institutions struggle to improve certification rates. One possible method to overcome system barriers to certification is the implementation of a unit-based study course to prepare ...
Source: Clinical Breast Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Fischer-Cartlidge E, Mahon S Tags: Clin J Oncol Nurs Source Type: research

Evaluation of a breast and colon cancer survivorship program.
This article describes a cancer survivorship program that addressed quality of life (QOL) changes related to chemotherapy. The program focused on adult breast and colon cancer survivors at a community oncology practice in the southeastern United States, and consisted of an educational visit designed to identify and address QOL changes that occurred as a result of chemotherapy. The QOL of Cancer Survivors (QOL-CS) survey administered before and after the visit analyzed QOL metrics, which were combined with program evaluation data to assess physical, psychosocial, social, and spiritual well-being changes that may have occurr...
Source: Clinical Breast Cancer - April 1, 2014 Category: Cancer & Oncology Authors: McCollum KH, Wood FG, Auriemma K Tags: Clin J Oncol Nurs Source Type: research

Variations in self-reported nausea, vomiting, and well-being during the first 10 days postchemotherapy in women with breast cancer.
Abstract Women with breast cancer undergoing chemotherapy experience nausea and vomiting, both common symptoms affecting quality of life. The aim of the current study was to describe how nausea, vomiting, and well-being vary during the first 10 days after chemotherapy in women with breast cancer. A pilot study with a repeated-measurements design was conducted at a Swedish county hospital where 39 women with breast cancer treated with adjuvant chemotherapy were observed. A structured 10-day diary was used for data collection. Of the 39 women in the study, 33 experienced nausea and 6 also experienced vomiting after ...
Source: Clinical Breast Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Oliva D, Sandgren A, Nilsson M, Lewin F Tags: Clin J Oncol Nurs Source Type: research

Marking wire placement for improved accuracy in thoracic spinal surgery.
CONCLUSIONS: This is a safe and practical approach to identify the level of interest in thoracic spinal surgery employing a marking wire. Its application merits consideration in any spinal case where X-ray localization could prove unsafe, particularly in cases lacking bony pathologies such as intradural tumors. PMID: 24635936 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 22, 2014 Category: Cancer & Oncology Authors: Ahmadi SA, Slotty PJ, Schröter C, Kröpil P, Steiger HJ, Eicker SO Tags: Clin Neurol Neurosurg Source Type: research

Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.
PMID: 24577843 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 3, 2014 Category: Cancer & Oncology Authors: Soliman AA, Csorba R, Ullrich A, Tsikouras P, Rath W, von Tempelhoff GF Tags: Clin Appl Thromb Hemost Source Type: research

Breast cancer: Enzalutamide-a new treatment for ER-positive disease.
Authors: PMID: 24514144 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 11, 2014 Category: Cancer & Oncology Tags: Nat Rev Clin Oncol Source Type: research

Breast cancer: Overcoming resistance with dual HER2 blockade.
Authors: PMID: 24514145 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 11, 2014 Category: Cancer & Oncology Tags: Nat Rev Clin Oncol Source Type: research

GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells.
ov A Abstract PURPOSE: The orphan, membrane-bound estrogen receptor (GPER) is expressed at high levels in a large fraction of breast cancer patients, and its expression is favorable for patients' survival. We investigated the role of GPER as a potential tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells. METHODS: The effect of GPER agonist G-1 in cell culture was used to determine whether GPER inhibit cell growth. The methylation status of GPER promoter was investigated by methylation-specific PCR. RESULTS: GPER-specific agonist G-1 inhibited breast cancer cell proliferation in concentration-depen...
Source: Clinical Breast Cancer - February 11, 2014 Category: Cancer & Oncology Authors: Weißenborn C, Ignatov T, Poehlmann A, Wege AK, Costa SD, Zenclussen AC, Ignatov A Tags: J Cancer Res Clin Oncol Source Type: research

MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer.
Abstract BACKGROUND: MicroRNAs (miRNAs) are small, non-coding RNAs (18-25 nucleotides) that post-transcriptionally modulate gene expression by negatively regulating the stability or translational efficiency of their target mRNAs. The aim of this study was to investigate the expression pattern of microRNA-107 (miR-107) in human breast cancer, and its potential role in disease pathogenesis. METHODS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to determine the expression level of miR-107 in 30 breast cancer specimens and adjacent normal breast tissues. MTT and colony form...
Source: Clinical Breast Cancer - February 10, 2014 Category: Cancer & Oncology Authors: Li XY, Luo QF, Wei CK, Li DF, Li J, Fang L Tags: Int J Clin Exp Med Source Type: research

ICAM-1 +469 A/G polymorphism and cancer risk: a meta-analysis involving 9375 subjects.
CONCLUSION: The evidence from current meta-analysis doesn't support the ICAM-1 +469 A/G polymorphism as a risk factor for cancer. Further studies are needed to validate these findings. PMID: 24482692 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 10, 2014 Category: Cancer & Oncology Authors: Wang Y, Jia L, Shen Y, Guo S, Wan C, Yang T, An J, Chen L, Wang T, Wen F Tags: Int J Clin Exp Med Source Type: research

ERK/CANP rapid signaling mediates 17β-estradiol-induced proliferation of human breast cancer cell line MCF-7 cells.
ERK/CANP rapid signaling mediates 17β-estradiol-induced proliferation of human breast cancer cell line MCF-7 cells. Int J Clin Exp Med. 2014;7(1):156-62 Authors: Wang GS, Huang YG, Li H, Bi SJ, Zhao JL Abstract OBJECTIVE: 17β-estradiol (E2) exerts its functions through both genomic and non-genomic signaling pathways. Because E2 is important in breast cancer development, we investigated whether its actions in promoting breast cancer cell proliferation occur through the non-genomic signaling pathway via extracellular signal-regulated kinase 1/2 (ERK1/2)/calcium-activated neutral protease (CANP). ...
Source: Clinical Breast Cancer - February 10, 2014 Category: Cancer & Oncology Authors: Wang GS, Huang YG, Li H, Bi SJ, Zhao JL Tags: Int J Clin Exp Med Source Type: research

Ultrasound-guided vacuum-assisted breast biopsy using Mammotome biopsy system for detection of breast cancer: results from two high volume hospitals.
Abstract Ultrasound-guided vacuum-assisted breast biopsy (VABB) has been recently regarded as a feasible, effective, minimally invasive and safe method for removal of benign breast lesions without serious complications. The frequency of detection of noninvasive malignant breast lesions by ultrasound-guided VABB is increasing. The aim of this study was to evaluate the role of the ultrasound-guided VABB using Mammotome biopsy system in the early detection of breast cancer. Retrospective review between January 2008 to March 2013 the First Affiliated Hospital, Zhejiang University School of Medicine and Taizhou Hospita...
Source: Clinical Breast Cancer - February 10, 2014 Category: Cancer & Oncology Authors: Pan S, Liu W, Jin K, Liu Y, Zhou Y Tags: Int J Clin Exp Med Source Type: research

Clinical implications of high NQO1 expression in breast cancers.
CONCLUSIONS: High-level expression of NQO1 appears to be associated with breast cancer progression, and may be a potential biomarker for poor prognostic evaluation of breast cancers. PMID: 24499631 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2014 Category: Cancer & Oncology Authors: Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, Chen L Tags: J Exp Clin Cancer Res Source Type: research

Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project.
Abstract The Japan Cancer Surveillance Research Group aimed to estimate the cancer incidence in Japan in 2008 based on data collected from 25 of 34 population-based cancer registries, as part of the Monitoring of Cancer Incidence in Japan project. The incidence in Japan for 2008 was estimated to be 749 767 (C00-C96). Stomach cancer and breast cancer were the leading types of cancer in males and females, respectively. PMID: 24503029 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 5, 2014 Category: Cancer & Oncology Authors: Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, The Japan Cancer Surveillance Research Group Tags: Jpn J Clin Oncol Source Type: research

Breast cancer: CALOR favours adjuvant therapy for ILRR of breast cancer.
PMID: 24492831 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 4, 2014 Category: Cancer & Oncology Authors: Errico A Tags: Nat Rev Clin Oncol Source Type: research

Breast cancer: Progress from NOAH study comes in twos.
PMID: 24492833 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 4, 2014 Category: Cancer & Oncology Authors: Hutchinson L Tags: Nat Rev Clin Oncol Source Type: research

Bilateral breast cancers.
Abstract An increasingly large proportion of women with unilateral breast cancer are treated with bilateral mastectomy. The rationale behind bilateral surgery is to prevent a second primary breast cancer and thereby to avoid the resultant therapy and eliminate the risk of death from contralateral breast cancer. Bilateral mastectomy has been proposed to benefit women at high risk of contralateral cancer, such as carriers of BRCA1 and BRCA2 mutations, but for women without such mutations, the decision to remove the contralateral breast is controversial. It is important to evaluate the risk of contralateral breast ca...
Source: Clinical Breast Cancer - February 4, 2014 Category: Cancer & Oncology Authors: Narod SA Tags: Nat Rev Clin Oncol Source Type: research

Genetics of breast cancer bone metastasis: a sequential multistep pattern.
Abstract Bone metastasis accounts for the vast majority of breast cancer (BC) metastases, and is related to a high rate of morbidity and mortality. A number of seminal studies have uncovered gene expression signatures involved in BC development and bone metastasis; each of them points at a distinct step of the 'invasion-metastasis cascade'. In this review, we provide most recently discovered functions of sets of genes that are selected from widely accepted gene signatures that are implicate in BC progression and bone metastasis. We propose a possible sequential pattern of gene expression that may lead a benign pri...
Source: Clinical Breast Cancer - February 4, 2014 Category: Cancer & Oncology Authors: Fazilaty H, Mehdipour P Tags: Clin Exp Metastasis Source Type: research

Meta-analysis of the cytotoxic T-lymphocyte antigen 4 gene +6230G/A polymorphism and cancer risk.
Abstract OBJECTIVES: Cytotoxic T-lymphocyte antigen-4 (CTLA4, CD152) is one of the most fundamental immunosuppressive cytokines that inhibits T-cell activation and terminates the T-cell response by blocking signals stimulated via CD28. A number of studies have assessed the association between CTLA-4 +6230G/A polymorphism and cancer risk. However, the results remain controversial. METHODS: In the present study, we performed a meta-analysis to derive a more precise estimation of the relationship. A comprehensive literature search was performed using the PubMed database for relevant articles published (updated t...
Source: Clinical Breast Cancer - February 4, 2014 Category: Cancer & Oncology Authors: Zhao HY, Duan HX, Gu Y Tags: Clin Transl Oncol Source Type: research

Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.
vaska J Abstract Mutations of the tumor suppressor TP53 are present in many forms of human cancer and are associated with increased tumor cell invasion and metastasis. Several mechanisms have been identified for promoting dissemination of cancer cells with TP53 mutations, including increased targeting of integrins to the plasma membrane. Here, we demonstrate a role for the filopodia-inducing motor protein Myosin-X (Myo10) in mutant p53-driven cancer invasion. Analysis of gene expression profiles from 2 breast cancer data sets revealed that MYO10 was highly expressed in aggressive cancer subtypes. Myo10 was require...
Source: Clinical Breast Cancer - February 3, 2014 Category: Cancer & Oncology Authors: Arjonen A, Kaukonen R, Mattila E, Rouhi P, Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, Virtakoivu R, Cao Y, Sansom OJ, Joensuu H, Ivaska J Tags: J Clin Invest Source Type: research

American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers.
PMID: 24493721 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 3, 2014 Category: Cancer & Oncology Authors: Lu KH, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, Kohlmann W, Lindor NM, Mulvey TM, Robinson L, Rubinstein WS, Stoffel EM, Snyder C, Syngal S, Merrill JK, Wollins DS, Hughes KS Tags: J Clin Oncol Source Type: research

Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures As Part of the American Society of Clinical Oncology Quality Oncology Practice Initiative.
CONCLUSION: We identified low rates of complete CFH documentation and low rates of referral for those with BC or CRC meeting guidelines for referral among US oncologists. Documentation and referral were greater for patients with BC compared with CRC. Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed. PMID: 24493722 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 3, 2014 Category: Cancer & Oncology Authors: Wood ME, Kadlubek P, Pham TH, Wollins DS, Lu KH, Weitzel JN, Neuss MN, Hughes KS Tags: J Clin Oncol Source Type: research

Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: 20-Year Results of a Randomized Trial.
CONCLUSION: Radiotherapy protects against recurrences during the first 5 years of follow-up, indicating that XRT mainly eradicates undetected cancer foci present at primary treatment. The similar rate of recurrences beyond 5 years in the two groups indicates that late recurrences are new tumors. There are subgroups with clinically relevant differences in risk. PMID: 24493730 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 3, 2014 Category: Cancer & Oncology Authors: Wickberg A, Holmberg L, Adami HO, Magnuson A, Villman K, Liljegren G Tags: J Clin Oncol Source Type: research

Toremifene for breast cancer: a review of 20 years of data.
This article will examine the rationale for the use of toremifene in the treatment of women with breast cancer and review data from 20 years of clinical experience with this agent. PMID: 24439786 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 24, 2014 Category: Cancer & Oncology Authors: Vogel CL, Johnston MA, Capers C, Braccia D Tags: Clin Breast Cancer Source Type: research

FDG Avidity at PET/CT During Adjuvant Hormonal Therapy in Patients With Breast Cancer.
Abstract BACKGROUND: We aim to retrospectively evaluate the impact of hormone therapy (HT) on FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT. PATIENTS AND METHODS: Three hundred eight patients with BC were scanned with PET/CT at 2 Italian institutions (mean time from diagnosis 4 yrs, range: 1-24 yrs). Main indications for PET/CT were elevation of tumor markers (34.4%) and clinical or radiological suspicion of relapse (65.6%). The diagnostic accuracy of FDG PET/CT was computed according to the standard method. Student t test was used to assess the mean differences betwe...
Source: Clinical Breast Cancer - January 15, 2014 Category: Cancer & Oncology Authors: Evangelista L, Redana S, Racca M, Geuna E, Vinante L, Zago G, De Carolis V, Ghiotto C, Saladini G, Varetto T Tags: Clin Nucl Med Source Type: research

National practice in antibiotic prophylaxis in breast cancer surgery.
Abstract BACKGROUND: Although breast cancer surgery is regarded as a "clean" surgery, surgical site infection (SSI) rates are higher than expected. There is no consensus regarding the use of antibiotic prophylaxis in elective breast surgery. The nationwide survey was conducted to determine the trend of antibiotic prophylaxis in breast cancer among Turkish surgeons. METHODS: The survey was sent to surgeons who are member of Turkish Surgical Association (TSA) via e-mail from TSA web address. A 15 item web-based survey consisted of surgeon demographics and the use of prophylactic antibiotic in patients...
Source: Clinical Breast Cancer - January 15, 2014 Category: Cancer & Oncology Authors: Eroglu A, Karasoy D, Kurt H, Baskan S Tags: J Clin Med Res Source Type: research

Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1.
CONCLUSIONS: The excellent potency, safety and synergistic profiles of this potent first-in-class Hec1-targeted small molecule TAI-1 show its potential for clinically utility in anti-cancer treatment regimens. PMID: 24401611 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 9, 2014 Category: Cancer & Oncology Authors: Huang LY, Lee YS, Huang JJ, Chang CC, Chang JM, Chuang SH, Kao KJ, Tsai YJ, Tsai PY, Liu CW, Lin HS, Lau JY Tags: J Exp Clin Cancer Res Source Type: research

A Randomized Controlled Trial to Verify the Efficacy of the Use of Ultrasonography in Breast Cancer Screening Aged 40-49 (J-START): 76 196 Women Registered.
CONCLUSIONS: It was the first large-scale randomized controlled trial carried out in Japan. The scheduled second examinations were completed at the end of fiscal 2012. Once the proportion of participants whose status is unclear has fallen to ≤5%, the authors plan to collate the data relating to the primary end points, and publish the results. PMID: 24407835 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 9, 2014 Category: Cancer & Oncology Authors: Ishida T, Suzuki A, Kawai M, Narikawa Y, Saito H, Yamamoto S, Tohno E, Sobue T, Fukuda M, Ohuchi N Tags: Jpn J Clin Oncol Source Type: research

Satisfying the needs of Japanese cancer patients: A comparative study of detailed and standard informed consent documents.
CONCLUSION: Informed consent can be a significant experience for a population with standard literacy skills, as long as the document is easily comprehensible. Such information should be provided in a format that corresponds with patient needs, education levels, and preferences. PMID: 24408900 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 9, 2014 Category: Cancer & Oncology Authors: Sato K, Watanabe T, Katsumata N, Sato T, Ohashi Y Tags: Clin Trials Source Type: research

TOP2A gene copy number change in breast cancer.
CONCLUSIONS: TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value. PMID: 24403186 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 8, 2014 Category: Cancer & Oncology Authors: Engstrøm MJ, Ytterhus B, Vatten LJ, Opdahl S, Bofin AM Tags: J Clin Pathol Source Type: research

The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
CONCLUSIONS: A statistically significant difference in breast cancer specific survival is seen in groups defined using Ki67 and receptor status, whereas histological grading was not a significant predictor of survival. Ki67 immunostaining provides prognostic information beyond traditionally assessed clinicopathological variables. PMID: 24403187 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 8, 2014 Category: Cancer & Oncology Authors: Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL, Boyages J Tags: J Clin Pathol Source Type: research

Weight change trajectory in women with breast cancer receiving chemotherapy and the effect of different regimens.
CONCLUSION: The trajectory of body weight change within two years after chemotherapy shows a trend of gradual ascent, followed by a small decline and a slight increase in the last 2·5 months. The chemotherapy regimen can predict the trend after controlling for other confounders; women on cyclophosphamide, methotrexate and fluorouracil have a steeper weight change. RELEVANCE TO CLINICAL PRACTICE: Nurses can inform women with breast cancer about the expected changes in body weight after chemotherapy to reduce their uncertainty. Future studies on effective interventions to minimise chemotherapy-induced weight...
Source: Clinical Breast Cancer - January 7, 2014 Category: Cancer & Oncology Authors: Liu LN, Wen FH, Miaskowski C, Lin YC, Wang JS, Jeng C, Chen ML Tags: J Clin Nurs Source Type: research

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401).
CONCLUSION: The efficacy of adding AC to TAM was not high for ER+, node-positive PMBC. However, adjuvant ACT therapy was considered to be effective for ER-, node-positive PMBC. PMID: 24395447 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 7, 2014 Category: Cancer & Oncology Authors: Shien T, Iwata H, Aogi K, Fukutomi T, Inoue K, Kinoshita T, Takahashi M, Matsui A, Shibata T, Fukuda H Tags: Int J Clin Oncol Source Type: research

Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells.
CONCLUSIONS: Our data suggests that SULT1A1 expression is regulated by NFI, as well as SULT1A1 copy number variation in human breast cancer cell lines. These data provide a mechanistic basis for the differential expression of SULT1A1 in different tissues and different physiological states of disease. PMID: 24393253 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 6, 2014 Category: Cancer & Oncology Authors: Yao-Borengasser A, Rogers LJ, Edavana VK, Penney RB, Yu X, Dhakal IB, Williams S, Kadlubar SA Tags: BMC Clin Pathol Source Type: research

Systemic Chemotherapy Interferes in Homocysteine Metabolism in Breast Cancer Patients.
This study aimed to evaluate homocysteine and its cofators (folic acid and vitamin B12) concentrations and platelet count at diagnosis of BC, 3 and 6 months after the beginning of chemotherapy treatment and to correlate them with clinical data. METHODS: Thirty-five BC patients were included; blood samples were obtained by venipuncture. Plasmatic Hcy and cofactors concentrations were measured by competitive chemiluminescent enzyme immunoassay method. Platelet count was done using an automated analyzer. Statistical analysis was performed using the software SPSS. RESULTS: During chemotherapy, homocysteine (P = 0.032) and vitamin B12 (P
Source: Clinical Breast Cancer - January 6, 2014 Category: Cancer & Oncology Authors: Yamashita EK, Teixeira BM, Yoshihara RN, Kuniyoshi RK, Alves BC, Gehrke FS, Vilas-Bôas VA, Correia JA, Azzalis LA, Junqueira VB, Pereira EC, Fonseca FL Tags: J Clin Lab Anal Source Type: research

An Individual Person Data Meta-Analysis of Preoperative Magnetic Resonance Imaging and Breast Cancer Recurrence.
We examined the association between preoperative MRI and local recurrence (LR) as primary outcome, as well as distant recurrence (DR), in patients with BC. METHODS: An individual person data (IPD) meta-analysis, based on preoperative MRI studies that met predefined eligibility criteria, was performed. Survival analysis (Cox proportional hazards modeling) was used to investigate time to recurrence and to estimate the hazard ratio (HR) for MRI. We modeled the univariable association between LR (or DR) and MRI, and covariates, and fitted multivariable models to estimate adjusted HRs. Sensitivity analysis was based on wom...
Source: Clinical Breast Cancer - January 6, 2014 Category: Cancer & Oncology Authors: Houssami N, Turner R, Macaskill P, Turnbull LW, McCready DR, Tuttle TM, Vapiwala N, Solin LJ Tags: J Clin Oncol Source Type: research

Breast Magnetic Resonance Imaging As It Is, in Contrast to How We Wish It to Be.
PMID: 24395864 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - January 6, 2014 Category: Cancer & Oncology Authors: Bleicher RJ Tags: J Clin Oncol Source Type: research